New Retina Radio
New Retina Radio

07.07.25

GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates

How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited for treatment? In part 1 of this 2-part series, moderator Judy Kim, MD, and panelists Sunir Garg, MD; Deepak Sambhara, MD, and Rishi Singh, MD, explore these questions in a brief (but enlightening) discussion. 

View full description +

MORE EPISODES

08.20.26

Comparing Ocular AEs in Next-Gen Treatments

Katherine Talcott, MD; Akshay Thomas, MD; and Nita Valikodath, MD, MS

08.18.26

The Story Behind LYTENAVA™: From FDA Approval to Retina Practice

Barry Kuppermann, MD, PhD; and Bob Jahr, CEO of Outlook Therapeutics

08.12.26

The Fellow Eye: Episode 6

Justin C. Muste, MD; David Fell, MD; Monia Reding, MD; and Benjamin Young, MD

08.05.26

ASRS '26: SOL-1 and TRUCKEE at 4.5 Years

Dilsher Dhoot, MD; and Carl Danzig, MD

07.16.26

New Retina Radio Journal Club w/ VBS: Clinical Features and Outcomes of IOFB Removal

Jordan Deaner, MD; Vaidehi Dedania, MD; and Rehan Hussain, MD

07.08.26

Barriers to Care, Patient Education, and Treatment Decisions in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.08.26

Evolving Practice Patterns and Dosing Strategies in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.08.26

Biomarkers, Imaging, and Early Treatment Decisions in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Show More